A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas Exotoxin A and diphtheria toxin

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Roy, Vincent ^a   Ghani, Karim ^a   Caruso, Manuel ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; AMIDE; DIPHTHAMIDE; DIPHTHERIA TOXIN; ELONGATION FACTOR 2; PROTEIN DPH1; PROTEIN DPH2; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE RIBOSE; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; CARBOXY TERMINAL SEQUENCE; CELL PROTECTION; CONTROLLED STUDY; DELETION MUTANT; FEMALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TARGET CELL; TOXIN ANALYSIS; ANIMAL; CELL PROLIFERATION; CHEMISTRY; CHO CELL; CRICETULUS; DOMINANT GENE; GENE DELETION; GENETICS; HAMSTER; HUMAN; METABOLISM; MUTATION; PHENOTYPE;

CRICETULUS GRISEUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS EXOTOXIN; VIBRIO CHOLERAE;

ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE RIBOSE; ADP RIBOSE TRANSFERASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DIPHTHERIA TOXIN; EXOTOXINS; GENE DELETION; GENES, DOMINANT; HUMANS; MUTATION; PHENOTYPE; VIRULENCE FACTORS;

EID: 78650819063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015753     Document Type: Article

References (54)

1. Collier RJ (2001) Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon 39: 1793-1803.
2. Deng Q, Barbieri JT (2008) Molecular mechanisms of the cytotoxicity of ADPribosylating toxins. Annu Rev Microbiol 62: 271-288.
3. Jorgensen R, Purdy AE, Fieldhouse RJ, Kimber MS, Bartlett DH, et al. (2008) Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae. J Biol Chem 283: 10671-10678.
4. Lyczak JB, Cannon CL, Pier GB (2000) Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2: 1051-1060.
5. Kipnis E, Sawa T, Wiener-Kronish J (2006) Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 36: 78-91.
6. Bjorn MJ, Vasil ML, Sadoff JC, Iglewski BH (1977) Incidence of exotoxin production by Pseudomonas species. Infect Immun 16: 362-366.
7. Nicas TI, Iglewski BH (1985) The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol 31: 387-392.
8. Miyazaki S, Matsumoto T, Tateda K, Ohno A, Yamaguchi K (1995) Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice. JMed Microbiol 43: 169-175.
9. Pavlovskis OR, Pollack M, Callahan LT, 3rd, Iglewski BH (1977) Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun 18: 596-602.
10. Matsumoto T, Tateda K, Furuya N, Miyazaki S, Ohno A, et al. (1998) Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 47: 303-308.
11. Matsumoto T, Furuya N, Tateda K, Miyazaki S, Ohno A, et al. (1999) Effect of passive immunotherapy on murine gut-derived sepsis caused by Pseudomonas aeruginosa. J Med Microbiol 48: 765-770.
12. El-Zaim HS, Chopra AK, Peterson JW, Vasil ML, Heggers JP (1998) Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies. Infect Immun 66: 5551-5554.
13. Fogle MR, Griswold JA, Oliver JW, Hamood AN (2002) Anti-ETA IgG neutralizes the effects of Pseudomonas aeruginosa exotoxin A. J Surg Res 106: 86-98.
14. Manafi A, Kohanteb J, Mehrabani D, Japoni A, Amini M, et al. (2009) Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol 9: 23.
15. Ohman DE, Burns RP, Iglewski BH (1980) Corneal infections in mice with toxin A and elastase mutants of Pseudomonas aeruginosa. J Infect Dis 142: 547-555.
16. Pillar CM, Hobden JA (2002) Pseudomonas aeruginosa exotoxin A and keratitis in mice. Invest Ophthalmol Vis Sci 43: 1437-1444.
17. Galazka A (2000) The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181 Suppl 1: S2-S9.
18. Danilova E, Jenum PA, Skogen V, Pilnikov VF, Sjursen H (2006) Antidiphtheria antibody responses in patients and carriers of Corynebacterium diphtheriae in the Arkhangelsk region of Russia. Clin Vaccine Immunol 13: 627-632.
19. Farizo KM, Strebel PM, Chen RT, Kimbler A, Cleary TJ, et al. (1993) Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis 16: 59-68.
20. Speranza FA, Ishii SK, Hirata R, Jr., Mattos-Guaraldi AL, Milagres LG (2010) Diphtheria toxin IgG levels in military and civilian blood donors in Rio de Janeiro, Brazil. Braz J Med Biol Res 43: 120-123.
21. Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Junior R (2003) Diphtheria remains a threat to health in the developing world-an overview. Mem Inst Oswaldo Cruz 98: 987-993.
22. Robinson EA, Henriksen O, Maxwell ES (1974) Elongation factor 2. Amino acid sequence at the site of adenosine diphosphate ribosylation. J Biol Chem 249: 5088-5093.
23. Van Ness BG, Howard JB, Bodley JW (1980) ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J Biol Chem 255: 10717-10720.
24. Van Ness BG, Howard JB, Bodley JW (1980) ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyldiphthamide and its hydrolysis products. J Biol Chem 255: 10710-10716.
25. Chen JY, Bodley JW (1988) Biosynthesis of diphthamide in Saccharomyces cerevisiae. Partial purification and characterization of a specific S-adenosylmethionine: elongation factor 2 methyltransferase. J Biol Chem 263: 11692-11696.
26. Moehring JM, Moehring TJ, Danley DE (1980) Posttranslational modification of elongation factor 2 in diphtheria-toxin-resistant mutants of CHO-K1 cells. Proc Natl Acad Sci U S A 77: 1010-1014.
27. Moehring TJ, Danley DE, Moehring JM (1984) In vitro biosynthesis of diphthamide, studied with mutant Chinese hamster ovary cells resistant to diphtheria toxin. Mol Cell Biol 4: 642-650.
28. Mattheakis LC, Shen WH, Collier RJ (1992) DPH5, a methyltransferase gene required for diphthamide biosynthesis in Saccharomyces cerevisiae. Mol Cell Biol 12: 4026-4037.
29. Mattheakis LC, Sor F, Collier RJ (1993) Diphthamide synthesis in Saccharomyces cerevisiae: structure of the DPH2 gene. Gene 132: 149-154.
30. Liu S, Leppla SH (2003) Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide, the target of bacterial ADPribosylating toxins. Mol Cell 12: 603-613.
31. Liu S, Milne GT, Kuremsky JG, Fink GR, Leppla SH (2004) Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol 24: 9487-9497.
32. Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, et al. (2009) Haploid genetic screens in human cells identify host factors used by pathogens. Science 326: 1231-1235.
33. Brown BA, Bodley JW (1979) Primary structure at the site in beef and wheat elongation factor 2 of ADP-ribosylation by diphtheria toxin. FEBS Lett 103: 253-255.
34. Pappenheimer AM, Jr., Dunlop PC, Adolph KW, Bodley JW (1983) Occurrence of diphthamide in archaebacteria. J Bacteriol 153: 1342-1347.
35. Jorgensen R, Merrill AR, Yates SP, Marquez VE, Schwan AL, et al. (2005) Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature 436: 979-984.
36. Ortiz PA, Ulloque R, Kihara GK, Zheng H, Kinzy TG (2006) Translation elongation factor 2 anticodon mimicry domain mutants affect fidelity and diphtheria toxin resistance. J Biol Chem 281: 32639-32648.
37. Chen JY, Bodley JW, Livingston DM (1985) Diphtheria toxin-resistant mutants of Saccharomyces cerevisiae. Mol Cell Biol 5: 3357-3360.
38. Fichtner L, Jablonowski D, Schierhorn A, Kitamoto HK, Stark MJ, et al. (2003) Elongator's toxin-target (TOT) function is nuclear localization sequence dependent and suppressed by post-translational modification. Mol Microbiol 49: 1297-2307.
39. Falquet L, Pagni M, Bucher P, Hulo N, Sigrist CJ, et al. (2002) The PROSITE database, its status in 2002. Nucleic Acids Res 30: 235-238.
40. Chen CM, Behringer RR (2005) OVCA1: tumor suppressor gene. Curr Opin Genet Dev 15: 49-54.
41. Webb TR, Cross SH, McKie L, Edgar R, Vizor L, et al. (2008) Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci 121: 3140-3145.
42. 1 arrest induced by Kluyveromyces lactis zymocin. Mol Microbiol 44: 865-875.
43. Liu S, Wiggins JF, Sreenath T, Kulkarni AB, Ward JM, et al. (2006) Dph3, a small protein required for diphthamide biosynthesis, is essential in mouse development. Mol Cell Biol 26: 3835-3841.
44. Bar C, Zabel R, Liu S, Stark MJ, Schaffrath R (2008) A versatile partner of eukaryotic protein complexes that is involved in multiple biological processes: Kti11/Dph3. Mol Microbiol 69: 1221-1233.
45. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE (2005) Gene therapy in the cornea. Prog Retin Eye Res 24: 537-559.
46. Densmore CL (2006) Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 3: 55-63.
47. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, et al. (2005) Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 12: 1494-1502.
48. Yates SP, Jorgensen R, Andersen GR, Merrill AR (2006) Stealth and mimicry by deadly bacterial toxins. Trends Biochem Sci 31: 123-133.
49. Sellman BR, Mourez M, Collier RJ (2001) Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292: 695-697.
50. Doyon Y, Selleck W, Lane WS, Tan S, Cote J (2004) Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 24: 1884-1896.
51. Roy V, Qiao J, de Campos-Lima P, Caruso M (2005) Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther 12: 169-176.
52. Ghani K, Cottin S, Kamen A, Caruso M (2007) Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther 14: 1705-1711.
53. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
54. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.